Patrys advances PAT-LM1 to clinical development
THE PHARMACY: Clinical stage biotechnology company Patrys Limited (ASX: PAB) has released an update on the development program for the company’s anti-cancer product, PAT-LM1.
Patrys said PAT-LM1 is the second IgM antibody in the company’s pipeline to enter clinical development.
The company explained PAT-LM1 is a natural human antibody that has shown much promise in preclinical development as a potential treatment for multiple types of cancer, including colon, lung, breast, ovary, pancreatic and various haematological cancers.
Recent laboratory experiments focused on the evaluation of the efficacy of PAT-LM1 in blood cancers including different types of leukaemias and lymphomas.
PAT-LM1 showed strong and specific binding to more than 90 per cent of tested lymphoma cell lines and patients samples.
Patrys said PAT-LM1 was able to induce cell death in mantle cell lymphoma and histiocytic lymphoma cells as well as bonding specifically and strongly to some very rare lymphoma types such as marginal zone B-cell and Burkitt lymphoma, indicating it may have broad therapeutic application covering the whole range of different lymphomas.
Despite there being numerous drugs on the market for lymphoma, Patrys said there is an unmet medical need especially in patients with relapsed and refractory disease.
The prognosis for these patients is poor and therefore the development of novel agents, such as PAT-LM1, is urgently needed.
The cell line development of PAT-LM1 for production has been successfully completed and early data indicate that the resultant yield from a GMP manufacturing run is likely to be much higher than yields achieved to date.
Patrys has now commenced the manufacturing process to produce PAT-LM1 for a future clinical trial.
“The results demonstrated in this preclinical work confirm the potential of PAT-LM1 as an effective therapy for a broad range of lymphomas,” Patrys Limited CEO Dr. Marie Roskrow said in the company’s announcement to the Australian Securities Exchange.
“Currently we anticipate that this antibody will be moved into clinical trial at the University of Würzburg where we will be working with the same clinicians who successfully executed the recent PAT-SM6 multiple myeloma trial.
“Professor Einsele and his team are very excited by the prospects for PAT-LM1 in treating patients with relapsed and refractory lymphomas.”
Email: info@patrys.com
Website: www.patrys.com
Source: Company announcement